Biomarkers in rheumatoid arthritis

Fabiola Atzeni, Rossella Talotta, Ignazio F. Masala, Sara Bongiovanni, Laura Boccassini, Piercarlo Sarzi-Puttini

Research output: Contribution to journalReview articlepeer-review


Biomarkers are important for guiding the clinical and therapeutic management of all phases of rheumatoid arthritis because they can help to predict disease development in subjects at risk, improve diagnosis by closing the serological gap, provide prognostic information that is useful for making therapeutic choices and assessing treatment responses and outcomes, and allow disease activity and progression to be monitored. Various biomarkers can be used to identify subjects susceptible to the disease and those with pre-clinical rheumatoid arthritis before the onset of symptoms such as rheumatoid factor and anti-citrullinated protein antibodies. They can be correlated with a risk of developing rheumatoid arthritis and can predict more bone erosions and severe disease progression. Biomarkers such as the erythrocyte sedimentation rate and C-reactive protein levels provide information about disease activity, while predictive biomarkers allow clinicians to assess the probability of a treatment response before starting a particular therapy particularly in the era of biological drugs. This move from traditional approaches to patient stratification and targeted treatment should greatly improve patient care and reduce medical costs.

Original languageEnglish
Pages (from-to)512-516
Number of pages5
JournalIsrael Medical Association Journal
Issue number8
Publication statusPublished - Jan 1 2017


  • Anti-TNF drugs
  • Biological drugs
  • Biomarkers
  • Rheumatoid arthritis (RA)
  • Rituximab

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Biomarkers in rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this